The harm-channel on the same exposure whose CV-event benefit is dose-dependent: marine omega-3 supplementation raises the risk of incident atrial fibrillation, and the risk rises with dose. This is the off-target counterweight to the ischemic benefit held on Vitamin and Mineral Supplements for Disease Prevention (VITAL null at 1 g/d; REDUCE-IT positive at 4 g/d) and Fish and Seafood Consumption (Lombardi dose-NMA). It does not touch the fish-as-food recommendation — this is an isolate-supplement finding. (inferred from Gencer et al., 2021)
The effect — dose-dependent AF risk
Gencer 2021, a gold SR+MA of 7 marine omega-3 CV-outcome RCTs (81,210 patients, weighted mean age 65, 39% female, weighted median follow-up 4.9 y), pooling incident/adverse-event AF:
«The weighted average follow-up was 4.9 years. In meta-analysis, the use of marine omega-3 fatty acid supplements was associated with an increased risk of AF (n=2905; HR, 1.25 [95% CI, 1.07-1.46]; P=0.013). In analyses stratified by dose, the HR was greater in the trials testing >1 g/d (HR, 1.49 [95% CI, 1.04-2.15]; P=0.042) compared with those testing <=1 g/d (HR, 1.12 [95% CI, 1.03-1.22]; P=0.024; P for interaction <0.001).» (Gencer et al., 2021)
«In meta-regression, the HR for AF increased per 1 g higher dosage of omega-3 fatty acids dosage (HR, 1.11 [95% CI, 1.06-1.15]; P=0.001).» (Gencer et al., 2021)
- Overall: HR 1.25 (1.07-1.46) — a ~25% relative increase in AF, absolute base rate ~1.3%/yr across the pool. (Gencer et al., 2021)
- Dose split (prespecified 1 g/d cutoff): high-dose >1 g/d 1.49 (1.04-2.15) vs low-dose <=1 g/d 1.12 (1.03-1.22), P-interaction <0.001 — the interaction stratification collapsed the between-trial heterogeneity (overall I2=54.6% -> low-dose I2<0.01%, high-dose I2=9.9%), which is itself evidence the dose axis is real. (Gencer et al., 2021)
- Dose-response slope: per 1 g/d, HR 1.11 (1.06-1.15) over a studied range of 1-4 g/d (residual I2=0.00%). The slope is estimated only within 1-4 g/d — not below 1 g/d, and not above 4; read it as monotone-over-the-studied-range, not a law to extrapolate. (Gencer et al., 2021)
The trial-level forest — where the dose signal lives
| Trial | Dose / form | AF HR or RR (95% CI) | Dose stratum |
|---|---|---|---|
| VITAL Rhythm | 1 g/d EPA+DHA | 1.09 (0.96-1.24) | low |
| ASCEND | 1 g/d EPA+DHA | 1.23 (0.98-1.54) (rate ratio) | low |
| GISSI-HF | 1 g/d EPA+DHA | 1.10 (0.96-1.25) | low |
| RP (Risk & Prevention) | 1 g/d EPA+DHA | 1.22 (0.93-1.61) | low |
| OMEMI | 1.8 g/d EPA+DHA (elderly post-MI) | 1.84 (0.98-3.45) | high |
| STRENGTH | 4 g/d EPA+DHA (carboxylic acid) | 1.69 (1.29-2.21) | high |
| REDUCE-IT | 4 g/d icosapent ethyl (EPA-only) | 1.35 (1.11-1.65) (RR) | high |
(OMEMI is listed at 1.84 in the source’s forest plot but 1.94 in its discussion text — same CI 0.98-3.45, P=0.06, non-significant either way; the forest value is used here. (Gencer et al., 2021))
The two statistically-significant single-trial signals (STRENGTH, REDUCE-IT) are both high-dose; every low-dose trial is individually non-significant, positive-leaning, and only the pool clears significance at 1.12.
The dose-vs-formulation confound — and why it is NOT purely a REDUCE-IT/mineral-oil artifact
The high-dose arm is dominated by EPA-only REDUCE-IT (4 g icosapent ethyl vs a contested mineral-oil placebo) plus STRENGTH and OMEMI, so dose is entangled with formulation and with a sicker stratum. But the overall AF signal is not an artifact of REDUCE-IT alone — it survives dropping it:
«The effect of marine omega-3 fatty acid supplements on the risk of AF events after excluding REDUCE-IT (the only trial without DHA) remained significant (HR, 1.23 [95% CI, 1.02-1.49]; P=0.038).» (Gencer et al., 2021)
and dropping the AF-hospitalization-only RP trial (HR 1.26, 1.04-1.52). So the AF harm is a class effect, not one trial’s placebo controversy — but Gencer cannot separate whether the steeper high-dose slope is dose or EPA-only formulation (no trial randomized dose head-to-head; the >1 g/d arm and the EPA-only arm are the same trials). REDUCE-IT’s own prior report was the seed of the concern:
«REDUCE-IT also reported an increase in a prespecified tertiary outcome of AF hospitalization in those randomized to active treatment compared with placebo (3.1% versus 2.1%; P=0.004).» (Gencer et al., 2021)
Synthesis — a same-exposure benefit/harm split by dose (type-A/G)
The decision-relevant move this opens (present in no single held page before it): omega-3 supplementation carries a dose-dependent AF harm that runs opposite its dose-dependent CV-event benefit. The held benefit evidence (Lombardi dose-NMA on Fish and Seafood Consumption; REDUCE-IT/VITAL on Vitamin and Mineral Supplements for Disease Prevention) puts the ischemic benefit above 1 g/d, concentrated in high-risk statin-treated strata; Gencer puts the AF harm on the same rising dose arm. So the two curves cross the same dose axis in opposite directions:
- General, replete adult on OTC ~1 g/d: the CV benefit is near-null (VITAL/low-dose stratum) and the AF harm is small (1.12, ~2 extra AF per the low absolute base rate) — a small-lever decision on both sides. The AF harm does not by itself contraindicate a low-dose capsule, but there is little benefit to weigh it against.
- High-dose prescription (4 g icosapent ethyl for high-TG established-CVD): the ischemic benefit is real (REDUCE-IT MACE ~25% down) but is bought with the 1.49 AF risk plus bleeding — a genuine net-effect trade, not a free lever. Gencer’s own framing:
«Because the benefit of omega-3 fatty acids also appears to be dose-dependent, the associated risk of AF should be balanced against the benefit on atherosclerotic cardiovascular outcomes.» (Gencer et al., 2021)
The clinical-implication the authors draw is a disclosure, dose-graded:
«The potential risk of developing AF should be discussed with the patients when prescribing marine omega-3 supplementation, especially when prescribing a higher dosage.» (Gencer et al., 2021)
(inferred from Gencer et al., 2021)
NOT independent of the held omega-3 evidence (shared trial base + authors)
This MA is not an independent type-E corroboration of the held omega-3 CV evidence — it re-pools the same trials and shares authors:
- Shared trial base: «Of those, 5 trials were already included in a previous meta-analysis of cardiovascular RCTs» (Gencer et al., 2021) (Hu 2019, the same pool the held CV-benefit evidence draws on), and its 7 trials include the held VITAL (Manson 2019), REDUCE-IT (Bhatt 2019), and the trials Lombardi 2020 pools.
- Shared authorship: Cook, Manson, and Albert are VITAL/VITAL-Rhythm investigators and co-authors here. The AUTHOR-LIST DIFF and MA-CONSTITUENCY tests both fail for independence.
So its relationship to the CV-benefit finding is a benefit/harm distinction on the same exposure,
not opposed claims (not a filed [[tension]]) and not independent backing — do not stamp
[E-independent]. It is the first source to weave the AF-harm cell, which was previously only a
one-line side-effect note (Lombardi’s AF 1.35 side-effect line on the Fish page; REDUCE-IT’s AF-hosp
3.1% vs 2.1%).
(inferred from Gencer et al., 2021)
Limits
- AF ascertainment is heterogeneous and mostly not adjudicated. «differences exist in the AF outcome assessment between trials. In ASCEND (main article), REDUCE-IT, and RP trials, participants with preexisting AF were not systematically excluded from the analysis, whereas in other trials, the analysis reported new-onset AF events or excluded participants with preexisting AF.» (Gencer et al., 2021) AF outcomes were centrally adjudicated in only VITAL and OMEMI; prespecified in only VITAL, OMEMI, STRENGTH. The sensitivity analysis restricting to new-onset AF held (HR 1.26, 0.85-1.87; no interaction with the not-excluded set 1.28, 1.11-1.48).
- Subclinical-detection inflation in the elderly signal. The largest absolute AF risk difference (OMEMI, >3%, in those >=75 y) came from a trial that «also used monitoring to capture AF events; thus, it is likely that more asymptomatic, subclinical cases were detected» (Gencer et al., 2021) — more ascertainment, not necessarily more clinically-actionable AF.
- Aggregate, not individual-patient, data — «this report is unable to undertake subgroup analysis by age or other patient-level characteristics» (Gencer et al., 2021), so the stratum flip (elderly, cardiac-morbid) is a hypothesis, not an estimated effect-modification.
- Dose vs formulation not separable (above); the studied dose range is only 1-4 g/d, so the slope says nothing below 1 g/d or above 4.
- Coherence, not validity (R1): the loop is open — no operation here grades the omega-3-dose -> AF association against a realized patient outcome, and AF is a mixed endpoint (hard arrhythmia burden vs subclinical/monitoring-detected).
Self-critique [run 2026-09-02, before commit — page minted]
- Not overclaimed. The AF risk is stated as an association with a dose-gradient, never a proven dose-causal law; the dose-vs-formulation confound and the studied-range limit on the meta-regression are stated explicitly. The general-adult decision-change is correctly the small one on both sides, and the high-dose prescription trade is framed as balance, not prohibition. No fish oil causes AF blanket reading survives; the food-vs-supplement firewall is stated.
- Not a fake tension. The relationship to the held CV-benefit evidence is filed as a benefit/harm
distinction on the same exposure (not-joined guard (ii): benefit and harm are different outcomes
on one exposure, not opposed answers to one question) — no
[[tension]]filed, nocontradicts:edge. - Not laundered-E. Independence is explicitly denied via the shared-trial-base (5/7 in Hu 2019;
includes held VITAL/REDUCE-IT) and shared-authorship (Cook/Manson/Albert) tests; no
[E-independent]token; confidence held atmedium(single gold MA, consistent dose-gradient and surviving-REDUCE-IT sensitivity, but heterogeneous unadjudicated AF ascertainment and the dose/form confound).